AqVida GmbH
PolandAll drugs from this manufacturer
-
The medicine is used in adults who are not eligible for stem cell transplantation, for the treatment of high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).
Dosage form: powder for preparation of injection solution
Active substance Dosage azacitidine 100 mg ATC: L01BC07
-
The medicine is used in adults (who are not eligible for stem cell transplantation) to treat high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).
Dosage form: powder for preparation of injection suspension
Active substance Dosage azacitidine 25 mg/ml ATC: L01BC07
-
This medicine is used to treat prostate cancer when the disease has progressed after other chemotherapy has been used.
Dosage form: solution for infusion, concentrate
Active substance Dosage cabazitaxel 20 mg/ml ATC: L01CD04
-
The medicine is used in adults (who are not eligible for stem cell transplantation) for the treatment of high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).
Dosage form: powder for preparation of injection suspension
Active substance Dosage azacitidine 25 mg/ml ATC: L01BC07
-
The medicine is used in adult patients for the treatment of high-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. These are diseases that affect the bone marrow.
Dosage form: powder for preparation of injection suspension or injection solution
Active substance Dosage azacitidine 25 mg/ml ATC: L01BC07